You are here: Welcome to the MPKB » Welcome to the MPKB » Marshall Protocol » Olmesartan (Benicar) » Patient response to olmesartan (Benicar)
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision		Previous revision
home:mp:olmesartan:response [10.13.2018] – [Decrease in inflammation] sallieqhome:mp:olmesartan:response [09.14.2022] (current) – external edit 127.0.0.1
Line 1: Line 1:
 ====== Patient response to olmesartan (Benicar)     ====== ====== Patient response to olmesartan (Benicar)     ======
 +
 +<relatedarticles> [[home:patients:grappling_uncertainty|Confronting uncertainty about the Marshall Protocol]],  [[home:physicians:concerns|Physicians' concerns and success rates for 5 Dx]], [[home:starting:physician:reluctant#specific_research|Independent research into Olmesartan]]</article>
 +
  
 Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, and it activates the innate immune response. Patients who begin the Marshall Protocol (MP) may experience either, both, or neither. According to one rough estimate, 25% of patients who begin the MP experience immediate symptomatic relief when they begin the olmesartan blockade, about 25% feel no different, and the other 50% will experience some adjustment symptoms. Even for MP patients who have a minimal initial reaction to olmesartan, the medication almost always ultimately has strong antibacterial effects resulting in immunopathology. For olmesartan to be effective, it has to be [[dosing|dosed regularly]]: 40mg every 6-8 hours. Olmesartan (Benicar) has two actions. It palliates symptoms by reducing inflammation, and it activates the innate immune response. Patients who begin the Marshall Protocol (MP) may experience either, both, or neither. According to one rough estimate, 25% of patients who begin the MP experience immediate symptomatic relief when they begin the olmesartan blockade, about 25% feel no different, and the other 50% will experience some adjustment symptoms. Even for MP patients who have a minimal initial reaction to olmesartan, the medication almost always ultimately has strong antibacterial effects resulting in immunopathology. For olmesartan to be effective, it has to be [[dosing|dosed regularly]]: 40mg every 6-8 hours.
Line 30: Line 33:
 <mainarticle> [[home:protocol:olmesartan#potent_anti-inflammatory|Potent anti-inflammatory]] </article> <mainarticle> [[home:protocol:olmesartan#potent_anti-inflammatory|Potent anti-inflammatory]] </article>
  
-Olmesartan is classified as an Angiotensin II Receptor Blocking (ARB) drug. When olmesartan binds and blocks the Angiotensin Receptor, it prevents fibrotic tissue from forming and [[http://www.joimr.org/phorum/read.php?f=2&i=53&t=53|decreases levels of Nuclear Factor Kappa B]], a protein that stimulates the release of inflammatory cytokines - proteins that generate pain and fatigue. The drop in cytokines results in less inflammation and oxidative stress.+Olmesartan is classified as an Angiotensin II Receptor Blocking (ARB) drug. When olmesartan binds and blocks the Angiotensin Receptor, it prevents fibrotic tissue from forming and [[https://www.joimr.org/phorum/read.php?f=2&i=53&t=53|decreases levels of Nuclear Factor Kappa B]], a protein that stimulates the release of inflammatory cytokines - proteins that generate pain and fatigue. The drop in cytokines results in less inflammation and oxidative stress.
  
 For this reason, [[dosing|higher doses or more frequent administration]] of olmesartan is strongly recommended during [[home:mp:managing_immunopathology|severe immunopathology]] and [[home:special:hospitals_emergencies|critical care situations]]. For this reason, [[dosing|higher doses or more frequent administration]] of olmesartan is strongly recommended during [[home:mp:managing_immunopathology|severe immunopathology]] and [[home:special:hospitals_emergencies|critical care situations]].
Line 38: Line 41:
  
  
 +<nodisp>
 ===== Notes and comments ===== ===== Notes and comments =====
  
   * Legacy content   * Legacy content
-    * http://www.marshallprotocol.com/forum32/1875.html f329 +    * https://www.marshallprotocol.com/forum32/1875.html f329 
-    * http://www.marshallprotocol.com/forum32/1195.html f345 +    * https://www.marshallprotocol.com/forum32/1195.html f345 
-    * http://www.marshallprotocol.com/view_topic.php?id=1080&forum_id=32&jump_to=38646#p38646 f1 +    * https://www.marshallprotocol.com/view_topic.php?id=1080&forum_id=32&jump_to=38646#p38646 f1 
-    * http://www.marshallprotocol.com/view_topic.php?id=1080&forum_id=32&jump_to=78974#p78974 f3 +    * https://www.marshallprotocol.com/view_topic.php?id=1080&forum_id=32&jump_to=78974#p78974 f3 
-    * http://www.marshallprotocol.com/view_topic.php?id=1784&forum_id=32&jump_to=158993#p158993 f59+    * https://www.marshallprotocol.com/view_topic.php?id=1784&forum_id=32&jump_to=158993#p158993 f59
 ===== References ===== ===== References =====
-   +   </nodisp> 
home/mp/olmesartan/response.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.